Who Paid My Doc
Eric Bendorf
Council Bluffs, IA Medical Doctor
NPI 1558447169 CMS profile 206352
201 Ridge St, Suite 214, Council Bluffs, IA 51503
General payments
$44,537
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Eric Bendorf of Council Bluffs, IA is reported in the CMS Open Payments database as having received $44,537 across 134 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,819 | 28 | |
| 2024 | General | $675 | 16 | |
| 2023 | General | $68 | 4 | |
| 2022 | General | $1,217 | 5 | |
| 2021 | General | $4,797 | 17 | |
| 2020 | General | $260 | 7 | |
| 2019 | General | $35,700 | 57 |
Beside peers
- Eric Bendorf
- Iowa median
- Middle half of Iowa
- National median
In program year 2025, general payments to Eric Bendorf were reported at $1,819. Among 7,876 Iowa profiles paid that year, the median was $123 and the middle half received between $40 and $397.
Show as a table
| Year | Eric Bendorf | Iowa median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $35,700 | $121 | $35–$425 | $163 |
| 2020 | $260 | $78 | $26–$234 | $114 |
| 2021 | $4,797 | $100 | $31–$311 | $132 |
| 2022 | $1,217 | $112 | $35–$349 | $149 |
| 2023 | $68 | $123 | $38–$380 | $160 |
| 2024 | $675 | $124 | $38–$421 | $164 |
| 2025 | $1,819 | $123 | $40–$397 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 1 drugPart D claims
54
Drug cost
$190
Branded share of claims
100%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 54 | $190 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 93 billing codesPaid by Medicare
$92,346
Medicare patients
280
Services billed
584
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 49% | |
| Cancer | 37% | |
| Ischemic heart disease | 30% | |
| Diabetes | 29% | |
| Heart failure | 27% | |
| Chronic kidney disease | 26% | |
| Depression | 22% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
134 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.